Previous 10 | Next 10 |
Ionis enters exclusive licensing agreement with Bicycle Therapeutics aimed at further advancing LICA technology - Exclusive rights to innovative peptide technology positions Ionis to further strengthen targeting capabilities of its LICA therapies PR Newswire CARLSB...
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle® ) technology, today announced an update regarding shareholder attendance at its 2021 Annual General Me...
Bicycle Therapeutics (BCYC): Q1 GAAP EPS of -$0.73 misses by $0.05.Revenue of $1.8M (+59.3% Y/Y) beats by $0.15M.Press Release For further details see: Bicycle Therapeutics EPS misses by $0.05, beats on revenue
- BT7480, the lead Bicycle tumor-targeted immune cell agonist, presented at AACR Annual Meeting 2021 “New Drugs on the Horizon” session; remains on-track for 2H'21 clinical trial start - Achieved significant recent progress across pipeline of Bicycle ...
- BT7480 to be presented in a “New Drugs on the Horizon” session; on-track to enter the clinic in 2H’21 Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bi...
- First milestone achieved in neuroscience collaboration with Dementia Discovery Fund and the Alzheimer’s Research UK Oxford Drug Discovery Institute - Significant advances made in the application of Bicycle technology against emerging antimicrobial and antiviral ta...
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle® ) technology, today announced the appointment of Jose-Carlos (“JC”) Gutierrez-Ramos,...
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ®) technology, today announced that management will participate in a fireside chat at the Oppenheim...
Bicycle Therapeutics (BCYC): Q4 GAAP EPS of -$0.83 misses by $0.32.Revenue of $3.85M (-27.1% Y/Y) beats by $0.19M.Press Release For further details see: Bicycle Therapeutics EPS misses by $0.32, beats on revenue
- Significant progress achieved across pipeline of Bicycle ® Toxin Conjugates (BTCs™) and tumor targeted immune cell agonists (TICAs™) - Cash of $136.0 million at December 31, 2020 expected to provide financial runway through multiple clinical milestones...
News, Short Squeeze, Breakout and More Instantly...
Bicycle Therapeutics plc Company Name:
BCYC Stock Symbol:
NYSE Market:
Bicycle Therapeutics plc Website:
2024-06-10 02:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Emerging clinical pharmacokinetic and safety profiles of Bicycle Toxin Conjugates ® demonstrate differentiation compared to antibody drug conjugates Trial-in-progress poster outlines registrational Phase 2/3 Duravelo-2 trial of BT8009, a Nectin-4 targeted Bicycle Toxin Conjugate,...
Financing includes participation from new and existing investors Strengthens balance sheet, with pro forma cash position of approximately $1.0 billion, extending expected financial runway into the second half of 2027 Supports ongoing advancement of pipeline with multiple clinical-...